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Abstract
Background: The Cooperative Prostate Cancer Tissue Resource (CPCTR) is a consortium of four geographically
dispersed institutions that are funded by the U.S. National Cancer Institute (NCI) to provide clinically annotated prostate
cancer tissue samples to researchers. To facilitate this effort, it was critical to arrive at agreed upon common data
elements (CDEs) that could be used to collect demographic, pathologic, treatment and clinical outcome data.
Methods: The CPCTR investigators convened a CDE curation subcommittee to develop and implement CDEs for the
annotation of collected prostate tissues. The draft CDEs were refined and progressively annotated to make them ISO
11179 compliant. The CDEs were implemented in the CPCTR database and tested using software query tools developed
by the investigators.
Results: By collaborative consensus the CPCTR CDE subcommittee developed 145 data elements to annotate the tissue
samples collected. These included for each case: 1) demographic data, 2) clinical history, 3) pathology specimen level
elements to describe the staging, grading and other characteristics of individual surgical pathology cases, 4) tissue block
level annotation critical to managing a virtual inventory of cases and facilitating case selection, and 5) clinical outcome
data including treatment, recurrence and vital status. These elements have been used successfully to respond to over 60
requests by end-users for tissue, including paraffin blocks from cases with 5 to 10 years of follow up, tissue microarrays
(TMAs), as well as frozen tissue collected prospectively for genomic profiling and genetic studies. The CPCTR CDEs have
been fully implemented in two major tissue banks and have been shared with dozens of other tissue banking efforts.
Conclusion: The freely available CDEs developed by the CPCTR are robust, based on "best practices" for tissue
resources, and are ISO 11179 compliant. The process for CDE development described in this manuscript provides a
framework model for other organ sites and has been used as a model for breast and melanoma tissue banking efforts.
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Background
Since the completion of the human genome project, there
has been a paradigm shift in the way biorepositories have
been utilized. Recent advances in the fields of genomics
and proteomics are providing novel ways of producing
experimental data using biospecimens. This shift has lead
to the development of robust clinical annotations for the
collected tissues, which easily allows comparative
research and in-depth analysis of data among multiple
institutions. This new paradigm is further exemplified in
2003 by the RAND Corporation's report on Human Tis-
sue Repositories that recommended "...the collection of
consistent and high-quality data associated with every
biospecimen and employing a standardized set of com-
mon data elements...;" for annotation as a best practice
[1].
Common data elements (CDEs) are annotations that are
collected in a uniform manner across multiple institu-
tions that allow sharing of data in a standardized format
and are defined in detail using a metadata dictionary.
In 1999 the National Cancer Institute (NCI), recognizing
the need for a multi-center effort in prostate cancer tissue
banking, issued an RFA for a consortium effort to collect
large numbers of clinically annotated prostate cancer
specimens for the research community [2]. This initiative
was created after a similar successful NCI Resource that
was created for breast tissue called the Cooperative Breast
Cancer Tissue Resource (CBCTR) [3,4]. In April 2000, four
academic institutions were funded by the NCI to form a
national prostate cancer tissue resource, the Cooperative
Prostate Cancer Tissue Resource (CPCTR). The goal of the
CPCTR is to collect large numbers of prostate cancer spec-
imens with accurate quality controlled and standardized
pathologic review of specimens and detailed, quality con-
trolled outcome data for use in biomarker validation stud-
ies, and to make this collection available to the research
community. During the initial phase of this project, many
of the experiences and basic infrastructural components
of the CBCTR were used as a model in developing the
CPCTR program. Specifically, the CBCTR data elements
were used by the CPCTR team to create common data ele-
ments (CDEs) for annotating the archival paraffin embed-
ded tissue samples in the prostate resource; the CBCTR
does not include frozen tissue collection.
The process of developing CDEs typically involves many
individuals and can take up to several months to arrive at
a draft that is based on complete consensus among those
involved. In the case of CPCTR there were pathologists,
urologists, cancer registrars, data managers, and cancer
researchers from five major medical centers and the NCI
Cancer Diagnosis Program who provided input and
approved changes to the developing CDEs along the proc-
ess of adopting the initial version. In this process it was
essential to 1) include experts from multiple disciplines,
2) consider the works of others creating similar CDEs,
and/or 3) consider established standards when available.
This communication describes the process of developing
CDEs for prostate cancer tissues that are banked by the
NCI's CPCTR [5,6].
Methods
Participating institutions
The Resource comprises four academic institutions:
George Washington University Medical Center (GWU),
Washington, DC; Medical College of Wisconsin (MCW),
Milwaukee, WI; New York University School of Medicine
(NYU), New York, NY; the University of Pittsburgh
(PITT), PA. The Resource has access to cases from a variety
of medical care settings that include academic medical
centers, as well as private, public, and Veterans Adminis-
tration hospitals. The participating hospitals are distrib-
uted across six states in the Northeastern and Midwestern
regions of the US. This varied access to cases allows
accrual of cases that reflect a wide diversity of patients
undergoing prostate cancer management in the United
States.
Human subjects protections
The CPCTR uses a decentralized sample and data collec-
tion and storage with a centralized data management
repository model. Each CPCTR institution has developed
its own local protocols with including consent language
describing its procedure to protect the confidentiality and
privacy of human subjects and has obtained local IRB
approval for all CPCTR activities. Tissue data records from
the cooperating institutions are submitted to a central
data manager (Information Management Services, Inc.
(IMS, Bethesda, MD) [16], contracted by the NCI). All
institutions assign a random, ten-digit number generated
by IMS to each record before submitting the data to the
central database. The only linkage to patient identity is
retained locally at each CPCTR institution. This ensures
that the central database has no links connecting records
to patients. In addition, de-identified datasets are gener-
ated from the central database for the research community
to query (the so-called safe harbor approach to HIPAA-
compliance) [7]. The ranges of ages are provided instead
of the date of birth and diagnosis to meet the compliant
requirements and research purposes.
Organization of the Resource
The CPCTR is governed by a Coordinating Committee
that has delegated tasks to several sub-committees. Figure
1 describes the three sub-committees that are involved in
the CDE development. The Coordinating Committee
includes the four principal investigators (PIs), four co-PIs,
a biostatistician, the NCI program leader, two centralBMC Cancer 2005, 5:108 http://www.biomedcentral.com/1471-2407/5/108
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database coordinators, and a member of the Research
Evaluation Panel (REP) that reviews request for tissues
and data by end-users. The Committee's main function is
to oversee all of the activities of the CPCTR. The Commit-
tee's role in developing the CDEs was to determine the
types of biospecimens (i.e. paraffin archival tissue, frozen
tissue, TMAs) the CPCTR will provide. The details of the
CPCTR organization are described in the Resource Man-
ual of Operations located at one of the Resource's websites
[8].
The pathology sub-committee includes at least one geni-
tourinary (GU) pathologist per member institution, a NCI
program leader, and ad hoc urologists and/or prostate
cancer researchers. Their major role is to develop standard
evaluation guidelines and propose pathology-specific
CDEs related to the different types biospecimens collected
to the CDE sub-committee.
The data manager sub-committee includes data managers
and cancer registrars from each of the four member insti-
tutions as well as the CPCTR biostatistician, two central
database coordinators, and the NCI program leader. This
sub-committee's main role is to implement and evaluate
the CDEs and to perform quality assurance checks on the
data collected at each member institution and to help
coordinate the distribution of tissue requests and the asso-
ciated data sets.
The CDE sub-committee includes multiple members from
each of the previously mentioned committees. This sub-
committee's role was to develop CDEs described in the
following section.
Development of the Common Data Elements
With guidance from the Coordinating Committee and the
other sub-committees, the CDE sub-committee's primary
tasked was to develop CDEs for demographics and clinical
history, specimen level annotation describing the overall
case where a bio-specimen was collected, block level
annotation which records information on individual
pieces or sections of the bio-specimen banked, and fol-
low-up information about treatment, vital status, bio-
chemical (prostate specific antigen [PSA] values) and
clinical recurrence to be included in the database. While
utilizing and learning from the experiences of several oth-
ers groups, the CDE sub-committee particularly took the
experiences of the CBCTR into considerations [3,4]. The
sub-committee also considered established open source
standards including the AJCC Cancer Staging Manual [9],
the NAACCR Data Standards for Cancer Registries [10],
the CAP Cancer Checklist [11], and other prostate specific
CDEs that were available through the NCI Center for Bio-
informatics (NCICB) [12,13].
Development of metadata for CDEs
Metadata is additional data developed to describes a spe-
cific CDE by following the ISO 11179 standard, which
"specifies that metadata should have a qualified name or
identifier, an authority who registers the name, a version-
ing history (allowing for modifications), a language or
origin, a statement relating to usage, a data typing state-
ment, and a definition that is unambiguous [14]." The
CPCTR data dictionary describing each of the common
data elements was generated by following the ISO-11179
standard for meta-data. The most current version of the
CDE data dictionary can be accessed at the CPCTR public
CPCTR Organization of the Resource Figure 1
CPCTR Organization of the Resource. The Coordinating Committee determines the types of biospecimens the CPCTR 
will provide. The Research Evaluation Panel (REP) from NCI is the committee in consultation with the Coordinating group. 
The sub-committees, pathology, CDE, data manager coordinate each other to develop the CDEs for different types of biospec-
imens that CPCTR will collect.BMC Cancer 2005, 5:108 http://www.biomedcentral.com/1471-2407/5/108
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database website [15]. This version of the documentation
was generated by the implementation of Oracle's
Application Server (v9.0.2) on a Compaq DL360 Server
running Windows 2000 with Service Pack 2. The applica-
tion, as shown on figure 2, uses the Oracle http server and
mod_plsql extensions to generate dynamic pages from the
database to the users.
Development of the CPCTR database
Once the initial set of CDEs was developed and approved
by the Coordinating Committee, it was used to create a
Microsoft Access database by IMS [16]. This database was
then distributed to allow each of the member institutes to
capture data on all of the tissue samples they will provide
to the Resource. Each member institute either utilized this
Access database or developed its own database based on it
utilizing the technologies that fit its own institutional
development environment. Two of the member institu-
tions created their own database using Oracle, while the
two other institutions modified the Access database to
collect other data elements unique to their local biospeci-
men collection efforts. By following each institutional
IRB's approved protocol, data were collected in the local
database. Although, they use different databases, data for
all the CDEs from each case were exported to the IMS cen-
tral database on a monthly basis in pre-defined formats in
excel worksheets with the IMS identifier that was ran-
domly generated and pre-assigned to each institution.
Once imported into the central database, data QA checks
are conducted to detect any missing essential CDEs or
CPCTR metadata dictionary application Figure 2
CPCTR metadata dictionary application. This is a screen shot of the Oracle mid-tier application used for adding or mod-
ifying active CDEs along with the associated metadata. It is also used for generating the CPCTR public query tool available at 
http://www.prostatetissues.orgBMC Cancer 2005, 5:108 http://www.biomedcentral.com/1471-2407/5/108
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possible data input errors including field and cross-field
checking (i.e. number of nodes positive >1, then pathol-
ogy nodal stage = pN1). The valid field options for each
data element are defined in the CDE description. Any
records with invalid or discrepant data items are censored
(i.e., removed from the available tissue samples for inves-
tigators) so they are not selected for an application request
until they are resolved. Resolutions are the responsibility
of the sending institution and are repaired and re-sent
with the next monthly data update. In addition, after the
initial implementation of any newly created CDEs, there
is a short pilot phase where the IMS data check quality
assurance review catches any errors and notifies the local
institute to resolve the problem.
Furthermore, all of the HIPAA's proscribed set of 18 data
elements was omitted from sample records to create a
public database [17] for the research community to use.
The de-identified data were also utilized by the IMS for
filling tissue disbursement to end-users.
Evaluation of the CDEs
The evaluation phase of the CDEs allowed the CPCTR to
examine the quality of data collected by each of the mem-
ber institutions. The evaluation, an ongoing effort, is car-
ried out at multiple levels by the data manager's sub-
committee and reported to the Coordinating Committee.
As previously mentioned, the initial evaluation is con-
ducted once any specific CDE is approved and changes to
Access database are made. A test export file is sent to IMS
to verify correct implementation of any new updates. IMS
performs a data check for accuracy and completeness and
notifies the local institution of any issues to resolve. The
second evaluation, conducted on a monthly basis, is the
one carried out by the Data manager's sub-committee
(QA checks on 10% of all new cases entered into their
local database and sent to IMS).
Finally, the data managers also re-evaluated all CDEs in
the entire central database once an initial benchmark of
2,000 cases submitted into the central database was
reached. The CDE sub-committee's tasks in this final
effort were to determine which CDEs were least populated
with valid values (e.g., the CDE "patient's history of other
cancers"), which valid values were least used to populate
a particular CDE (e.g., the CDE "vital status" has valid val-
ues of 'alive, alive with prostate cancer, dead, dead with
prostate cancer, dead with autopsy, dead with warm
autopsy'), and which CDEs created difficulties in collec-
tion (e.g., distant site 1 at the time of diagnosis, date of 1st
recurrence, 1st non-prostate recurrence, and distant site of
1st recurrence). Standards for the discontinuation, consol-
idation, or expansion of CDEs were decided on by com-
mittee consensus after discussion and review. Individual
institutions could choose to keep discontinued CDEs
locally if they were associated with specific institutional
research goals.
Results
Inventory of resources for CPCTR
At each institution, archival specimens from radical pros-
tatectomies, diagnostic needle biopsies, and surgically
removed metastatic tissue specimens from 1989 to
present were identified from the pathology records. At the
time of compilation of this manuscript (October 2004),
there were more than 6,000 annotated cases of prostate
cancer specimens with data on over 30,000 archival paraf-
fin-embedded tissues blocks and 5,800 frozen tissue
blocks, and two sets of tissue microarrays (TMAs) that are
currently available to the research community. The major-
ity of these cases consisted of archival paraffin blocks from
surgical patients treated between 1989 and 1998. The
remaining cases are recent cases (accrued from 1999
onwards) with prospectively banked tissue (both frozen
and paraffin embedded tissue). At some CPCTR sites (e.g.
Medical College of Wisconsin, George Washington Uni-
versity, and University of Pittsburgh), blood, serum, and
urine samples have also been collected prior to or at the
time of surgery from prospectively banked radical prosta-
tectomy patients. The Resource has also accrued diagnos-
tic needle biopsy specimens from at least 2,209 of the
radical prostatectomy patients that are entered into the
Resource and from 940 prostate cancer patients who did
not undergo a radical prostatectomy. The latter samples
represent patients who were not eligible for prostatec-
tomy, and received radiation or hormonal therapy, under-
went watchful waiting or have died from other causes
including other cancers.
Development of the CDEs
The Coordinating Committee [18] created four main data
categories for annotation of the types of specimens
banked as a guideline for the CDE development process.
The four main categories were: 1) Patient demographics
and clinical history data; 2) Specimen annotation, which
records basic overall information on a particular event
where a bio-specimen was collected as a result of a clinical
intervention and/or a specific banking event for research
based on a protocol; 3) Block level annotation which
records attributes detailing each specimen's paraffin or
frozen tissue block entered into the Resource (so-called
"matrix blocks") from a particular case; and 4) Treatment
and outcomes annotation, which records data that is col-
lected in a longitudinal manner through an "event table"
so that outcomes based research can be performed. Sub-
categories and additional data elements for each of the
four main groups are described in figure 3.
The CDE sub-committee identified and developed CDEs
within each of the four main categories by reviewing dataBMC Cancer 2005, 5:108 http://www.biomedcentral.com/1471-2407/5/108
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CPCTR CDE categories Figure 3
CPCTR CDE categories. Four main categories of CDEs and the sub-data types collected. Detail description of each CDE 
under these four main categories and its sub-groups can be found in the CPCTR CDE data dictionary.
I. Patient Demographics/Clinical History  
 Date of birth 
 Race
 Age at diagnosis 
 Family history of prostate cancer 
 Procedure
 Date of Procedure 
 Date of Diagnosis 
 Specimen availability 
II. Specimen level annotation (overall case accession attributes) 
 Prostate
 Histology 
 Gleason Grade 
 Size of tumor 
 Presence of PIN 
 Tumor attributes (Extracapsular, perineural, angiolymphatic invasion, etc…) 
 Staging
 Biopsy 
 Histology 
 Gleason Grade 
 Percentage of biopsy occupied by tumor 
 Presence of PIN 
 Lymph node 
 Number positive/examined 
 Metastasis case 
 Organ involved 
III. Block level annotation (individual block attributes) 
 Prostate (Paraffin and Frozen blocks) 
 Histology 
 Gleason Grade 
 Size of tumor 
 Presence of PIN 
 Tumor attributes (Extracapsular, perineural, angiolymphatic invasion, etc…) 
 Biopsy 
 Histology 
 Gleason Grade 
 Presence of PIN 
 Tumor attributes (Extracapsular, perineural, angiolymphatic invasion, etc…) 
 Lymph node 
 Size of tumor 
 Extracapsular extension 
 Metastasis blocks 
 Size of tumor 
 Therapy effect 
IV. Treatment and outcomes annotation (Longitudinal data) 
 Bio-markers (i.e. PSA) 
 Treatment 
 Recurrence/Progression 
 Clinical Recurrence 
 Biochemical Recurrence 
 Last Follow up date/Vital status BMC Cancer 2005, 5:108 http://www.biomedcentral.com/1471-2407/5/108
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elements created by other existing consortiums and open
sources. Specifically, the CDE sub-committee used the
CBCTR core model and expanded it to include detailed
block level annotation, including multiple types of tissue
[i.e. prostatectomy (frozen and paraffin), biopsy, lymph
node, metastasis]. In addition, the CDE sub-committee
developed a set of data elements to address clinical out-
come by expanding treatment and recurrence fields to
include initiation and completion dates so that a clinical
timeline of major events can be followed over time for a
patient's course of disease. These annotations importantly
include the prostate tumor serum marker (PSA) critical to
determining biochemical recurrence. The group also used
established standards from the American Joint Commis-
sion on Cancer (AJCC) for the staging data elements, the
College of American Pathologists (CAP) check list for the
annotation at a specimen level, and some elements from
the North American Association of Central Cancer Regis-
tries (NAACCR) for demographics and follow up data ele-
ments [9-11].
Common Data Elements
The Resource database consists of a set of 145 common
data elements (CDEs) which capture the clinical, patho-
logic and tissue sample inventory data for each case. The
data set for the biopsy and metastatic specimens from
patients who did not undergo surgery includes many of
the radical prostatectomy CDEs with slight variations on
individual block descriptors. Each of the data elements is
fully described as a set of features conforming to the ISO-
11179 standard for meta-data [14]. The data dictionary
detailing these CDEs and the associated paper data forms,
used by the pathologists and data managers for capturing
data, is included as an attachment to this article. The most
current version of the approved CDEs can be found on the
CPCTR public database website [15].
In order to facilitate material tracking and the identifica-
tion of specimen-specific characteristics needed during tis-
sue send out or processing, the Resource captures the
pathology characteristics of the tissue specimens at the
level of individual paraffin tissue blocks and frozen tissue
slices for each case. These annotations were named "block
matrix" because the annotations are spreadsheet-like in
character. From each case the "block matrix" was applied
to paraffin blocks of cancer that were selected for inclu-
sion in the Resource collection, with annotation for each
block of histologic tumor type, size of tumor focus,
Gleason grade, presence of high grade prostatic intraepi-
thelial neoplasia (HGPIN), and presence of perineural,
seminal vesicle, or lymphovascular invasion. A detailed
annotation is also used for a lymph node matrix block of
cases where metastatic tumor was identified in lymph
nodes removed at the time of radical prostatectomy. The
two other types of matrix blocks annotated by the
Resource are blocks containing HGPIN (but no cancer),
and benign prostate tissue from areas adjacent to tumor
containing prostatectomy blocks, which may be used as
one form of "control" tissue.
The CDE sub-committee also determined that 14 of the
CDEs developed were critical (or 'required') data fields,
listed on figure 4. These critical data items are the mini-
mum data elements required for a case to be eligible for
inclusion in the Resource. Any records with missing or
invalid critical data items are rejected and the
corresponding institution is responsible for resolving the
issue. In additional, there are 17 "conditional" required
data items.
Re-evaluation of CDEs
Annual re-evaluation of the CDEs by the data managers of
the CPCTR is conducted to determine which CDEs are
most useful for routine tissue and data collection and for
long-term updates by all the sites. An overview of the
process is described in figure 5. If any desired CDE was
found to be poorly collected from a quality control or
practical standpoint, discussions were initiated to modify
the data collection process through discussions with the
cancer registrars and data managers. For example, the
evaluation of the data collected for recurrence and pro-
gression showed that the initial definitions for CDEs
caused difficulties for the data managers collecting this
information prompting re-definition of those CDEs. The
definitions of the CDEs and their metadata were found to
be critical in the clear understanding of what information
was to be collected. For example, the initial collection of
data related to the CPCTR's CDE for distant metastasis
and recurrences were entered in multiple fields (i.e., dis-
tant metastasis at the time of diagnosis, distant site of 1st
recurrence, 1st  non-prostate recurrence and metastatic
lymph nodes). Review revealed that these data elements
were being poorly collected in quantity (<1% of cases
with a valid response) and quality (75% cases with dis-
crepancies when compared to clinical staging or PSA
recurrence data). A discussion with the cancer registrars
revealed inconsistent application of the definitions for
distant metastasis and recurrence. Consequently, the
CDEs were modified and re-defined, and subsequent re-
evaluation of the collected cases revealed improved data
collection.
The first generation CDEs that were determined to result
in poorly collected data from all the sites were eliminated
and no longer collected after a review of the initial 2600
cases entered into the Resource. For example, a CDE for
smoking history attempted to collect multiple values such
as "current smoker, never smoked, past smoker, smoker
(current or past unknown), and unknown". These values
were available for only a limited number of cases (44% ofBMC Cancer 2005, 5:108 http://www.biomedcentral.com/1471-2407/5/108
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CPCTR Critical Data Fields Figure 4
CPCTR Critical Data Fields. The critical data fields are divided into two categories$: 1) Required fields, which are essential 
and must be entered into the database for a case to be accepted. 2) Conditional required fields, which must be filled out when 
the respective tissue matrix is entered into the Resource.
Required Fields:*
* Records submitted with missing or invalid data in any one (or more) of these fields (indicated with a single 
asterisk) will not be loaded into the central database.  The respective site will receive a report indicating which 
record(s) have been loaded and which rejected and why.  The site must correct the error and resubmit the 
record to the central database.
1 . C a s e   I d e n t i f i e r *           C D E # 4  
2. Race*
@             C D E # 5
3. Birth date*
^            C D E # 8
4. Date of Diagnosis/Date of biopsy proven  cancer*^      CDE#11 
5. Are  Prostatectomy  specimens  available?*      CDE#13 
6. Are  Biopsy  specimens  available?*         CDE#14
7. Are  Regional  Lymph  Node  specimens  available?*      CDE#15
8. Are  Metastatic  specimens  available?*        CDE#16
9. Are  Plasma  samples  available?*         CDE#17
10.Are  Serum  samples  available?*         CDE#18
11.Are  Red  Blood  Cells  (RBCs)  available?*        CDE#19
12.Are Peripheral Blood Mononuclear Cells (PBMCs) available?*        CDE#20
1 3 . D a t e   L a s t   K n o w n   A l i v e *           C D E # 1 1 6
14.Vital Status*
@            C D E # 1 1 8
Conditional Required Fields:**
**Any Case with at least ONE SPECIMEN/BLOCK with tumor present, whether it be prostatectomy, biopsy, 
regional lymph node, or metastatic tissues, can qualify the case to be included in the CPCTR Resource.
Therefore, the respective CDEs below must be filled in for the specific tissue matrix (i.e. Prostatectomy, biopsy, 
regional lymph nodes, or metastatic tissues) available to the Resource.
15.Paraffin  Block  Matrix:  Block  number**        CDE#28,44
16.Paraffin Block Matrix: Most Prominent Histological Type of Invasive Cancer **
@ CDE#29,45
17.Paraffin  Block  Matrix:  Primary  Gleason  Grade**       CDE#30,46
18.Paraffin  Block  Matrix:  Secondary  Gleason  Grade**      CDE#31,47
19.Date  of  Prostatectomy**          CDE#61
20.Is Residual Carcinoma Present at Prostatectomy?**
 @      C D E # 6 2
21.Most Prominent Histological Type of Invasive Cancer**        CDE#64
22.Prostatectomy: Primary Gleason Grade**
@       C D E # 6 6
23.Prostatectomy: Secondary Gleason Grade**
@       C D E # 6 7
24.Prostatectomy: Gleason Sum Score**
@        C D E # 6 8
25.Nodes Examined**
@           C D E # 8 1
26.Nodes Positive**
@           C D E # 8 2
27.pT Stage**
@            C D E # 1 0 9
28.pN Stage**
@            C D E # 1 1 0
29.pM Stage**
@            C D E # 1 1 1
30.Therapy  matrix:  Per  Initial  Treatment  Plan?  *       CDE#122
ub 3 1 . S s e q u e n t   P r o s t a t e c t o m y : *         C D E # 1 4 3
___________________________________ 
^Year must be valid and not unknown or missing. 
@Field may be unknown, but must not be blank. 
$Based on the CPCTR Data Dictionary Version 22 (9/14/04) BMC Cancer 2005, 5:108 http://www.biomedcentral.com/1471-2407/5/108
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Re-Evaluation of CDEs Figure 5
Re-Evaluation of CDEs. The flow chart describes the re-evaluation process involved for validating the CDEs. Any changes 
made after this process, usually eliminates discrepancies and difficulties with the data collection process. In addition, the data-
base also shows an increase in number of fields being populated with valid values and a decrease in "unknown" values.
Initial testing
of newly
developed
CDEs
Adding New CDEs
(i.e. Expanding resource
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cases with data), which many of them were inconsistently
applied because of ambiguous definitions and subjective
reporting from the clinical charts. These concerns led the
CPCTR Coordinating Committee [18] to eliminate this
CDE. However, each institution that elected to resume
collecting discontinued CDEs were allowed to locally, but
were not reported to the central database.
The Coordinating Committee also re-evaluates the
resource as a whole periodically to meet the needs of the
prostate research community. The CDE sub-committee is
charged to add new CDEs based on the needs of the
researchers and addition of new resource materials (e.g.,
biopsy only specimens, frozen matrix blocks, TMAs, and
metastatic tissue blocks). The Coordinating Committee
has added dates to many of the CDE categories to be able
to examine the timeline of major events that may occur
for each patient during his course of disease. This "event
table" has resulted in a better picture and assessment of
the inter-related characteristics of patient treatments and
outcomes.
Once the changes of the CDEs were approved, the local
and central databases were modified accordingly. The
existed data were programmed to be mapped and stored
to the updated databases. The local dataset from each site
was queried and sent to the central database following the
requested format and validated to ensure the correction of
the CDEs updating.
Discussion
In order to develop any biospecimen resource with high
quality specimen annotation, the initial process of build-
ing the resource involves significant time and commit-
ment from many experts from various disciplines. Open
discussions and input from all potential parties with a
stake in the outcome is crucial to any such developmental
work. The process of developing the CDEs for the CPCTR
has attested that this approach can successfully lead to the
implementation of robust prostate tissue CDEs that guide
the collection of quality data at over 18 different institu-
tions or hospitals [6,19,20].
Success depends on the ability to collect data using CDEs
that have been evaluated by a working group that provides
inputs from various experts. The CPCTR CDE sub-com-
mittee included organ specific clinicians (pathologists
and urologists), informaticians, biostatisticians, data
managers, cancer registrars, and research scientists. Clini-
cians were primarily responsible for providing the foun-
dation of data elements as they reflected the current
standard of information used in patient care decisions,
while attempting to project at least five years into the
future for additional data that may become clinically sig-
nificant. Likewise, research scientists provided input on
data elements that would be crucial in the evaluation of
current or proposed prostate cancer research with respect
to the detection, diagnosis, prognostication, and treat-
ment of prostate cancer. Thus the result was the creation
of datasets that should provide value to the research com-
munity when requested from the resource for years to
come.
Local data collection methods vary at each institution
based on personnel. Some sites have cancer registries
responsible for obtaining patient follow up data, while
others obtain data from their registry systems or have
independent nurses or data managers who extract data
from Urology offices by reviewing charts. Thus, it was
important to include these nurses, data managers, and
cancer registrars who are the main data collectors for the
tissue banking resource in CDE development. Their input
on the types of data and meta-data available for collection
proved to be crucial in aggregating highly quality annota-
tion data for the bio-specimens. Moreover, the definitions
of the CDEs and their associated metadata need to be
clearly understandable to all those who collect data. For
example, in order to collect quality data, the collectors
need to understand 1) the fundamental definition of the
data element (i.e., date of diagnosis), 2) how that data ele-
ment will be collected (e.g. 11/2003 vs. Nov. 2003 vs. 11/
03, etc), 3) what are the consensus acceptable values or
codes are for the data element (e.g., precise date of birth,
not calculated from clinical records where the "patient
appears to be a well developed 75 year old"), and 4) what
the acceptable data format is for inclusion into the central
database (e.g., dates as integers not character strings).
Through the use of ISO 11179 compliance standards, the
goals of collecting annotation data of high quality was
achievable, and emphasize the consensus approach used
by CPCTR as being critical to successful CDE creation.
Although the concept of formalized metadata is fairly
straight forward, it has been rarely incorporated by clini-
cal and research groups building databases [14].
Another demonstration of the benefit by CPCTR CDEs is
evident from the implementation of the TMA data
exchange specification sponsored by the Association of
Pathology Informatics (API) [21]. This specification has
been used to provide a supplemental XML (Extensible
Markup Language) file of the data describing each of the
cores in the TMA slides provided to researchers through
the CPCTR [22]. The CDEs allow the Resource to directly
port data elements and associated metadata directly into a
TMA file that complies with the API's TMA specification
document and that contains a protected namespace for
the CPCTR metadata. These study cases show the exam-
ples that well developed CDEs can benefit comparative
research and in-depth analysis of data among multiple
institutions and studies. The only way in which informa-BMC Cancer 2005, 5:108 http://www.biomedcentral.com/1471-2407/5/108
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tion from multiple databases can truly be shared and
made useful is through the careful use of clearly defined
metadata and CDEs [23].
Informaticians and database developers provided the
structural link that brought the CDEs together in the data-
base, addressed technical issues, and provided guidance
related to implementation of the CDEs at local institu-
tions. The success of the CPCTR CDEs is shown by their
implementation at four separate institutions using four
different databases, thus demonstrating the ease at which
these standards can be copied and distributed across insti-
tutions. Regardless of which type of database is used
locally, each site is responsible for mapping their data dic-
tionary to the CPCTR CDEs when their data is sent to IMS
to be shared. At each individual institution additional
data is collected that is pertinent to institution-specific
research goals. Yet this incorporation of the common
CDEs allows institutions to share data and results across
groups while maintaining the autonomy of their research
objectives.
Furthermore, having the ability to collect high quality
"simple" data elements that have been agreed upon by a
working group is crucial for the overall quality of quanti-
tative analysis of inter-institutional data. Collecting sim-
ple, yet uniform and comprehensive data annotations in
a common database for research across multiple institu-
tions, each with various capabilities of collecting the data
(manual review of medical charts, cancer registry systems,
and interfaces to legacy systems), vastly increases the sta-
tistical power of research efforts and has the potential to
identify common trends and issues in cancer care. It is crit-
ical that these trends and issues be addressed if we are to
find methods to reduce the cancer burden and cancer pain
and suffering as is the goal of the NCI [24]. The value of
tissue banks and the informatics that support these goals
are clearly outlined in the NIH and NCI strategic road-
maps [25].
Conclusion
Recently, there has been an increasing number of interna-
tional [26-32] as well as national and state-wide
[20,33,34] initiatives that have promoted formation of
large research consortia and encourage these groups to
share both tissue and data. Currently, many tissue banks
such as the CBCTR [3,4], CHTN [35], CFR [36], SPOREs
[37], EDRN [13,38] and the PCABC [20] involve multiple
institutions. These biorepositories vary in their data col-
lection and tissue collection methodologies. However, the
necessity for well annotated tissues that can be re-anno-
tated with experimental data has driven many of these
multi-institutional collaborations to develop standards of
sharing data with other groups. Currently, the CPCTR
CDEs are specifically related to the available prostate tis-
sue resources and clinical data, while experimental data
generated from these tissue specimens are not required to
be submitted to the resource. However, publications
resulting from the use of CPCTR tissues are obliged to
credit the Resource, allowing the results to be correlated to
or compared with other studies using similar CDE stand-
ards. Other initiatives such as the Shared Pathology Infor-
matics Network or SPIN [19], the Early Detection
Research Network or EDRN [38] and the Cancer Biomed-
ical Informatics Grid initiative or CaBIG [39] can perform
follow-up studies by linking their results to CPCTR
derived studies by using the common CPCTR CDEs. This
also allows for meta-analysis of data across studies
through the CPCTR CDEs, resulting in improved statisti-
cal power and further detailed analysis. Thus, expanding
the CPCTR dataset by combining tissue with experimental
data will have tremendous value in enhancing cancer
research [40].
Based on the experience of developing CDEs for the
CPCTR, the following sequential strategies can be recom-
mended for other research groups involved in future CDE
development efforts.
Initial several months to a year:
• Decide what CDEs the resource will need using a com-
mittee driven consensus process that include all major
stakeholders
• Utilize as a starting point similar CDE initiatives already
developed by others and build upon their standards
• Consult a variety of experts, including those that will be
collecting the data particularly tissue bankers, cancer reg-
istrars and data managers
Next few months:
• Draft a CDE data dictionary which includes not only the
structured data, but also precise data field definitions and
a consideration of metadata (data that describes the orig-
inal data)
• Identify the essential/required data elements and ratify
them through a consensus process
• Modify or approve CDEs after discussions with all key
parties and build consensus among them and any other
external experts
• Create corresponding data entry paper forms/data entry
interface to central database
Subsequent few months:BMC Cancer 2005, 5:108 http://www.biomedcentral.com/1471-2407/5/108
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• Implement CDEs
• Test/Pilot phase: sharing of data with central database
Continuously ongoing efforts:
• Re-evaluate CDEs and their data values (every year or
after set accrual targets)
• Develop quality assurance, quality control and quality
improvement protocols to fully develop the CDEs (mini-
mum of once per year quarterly of semi annually or 10%
of new data set, which is the current norm for CPCTR)
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